Key FDA reform bills could be undermined by pre-emption clause
This article was originally published in Clinica
Executive Summary
US House Democrats drafted a package of Food and Drug Administration reform bills late last week that included a few tiny lines that caused a big fuss at a hearing on Tuesday June 12. Those lines would prohibit FDA law from pre-empting state court damage claims that opponents say could potentially jeopardise passage, writes April Fulton.
You may also be interested in...
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.